

Cancer associated thrombosis

2nd to 3rd March 2019

Thromboembolism frequently complicates the course of malignancy, particularly in the setting of medical and surgical anti-cancer treatments. Cancer associated thrombosis (CAT) can involve both the venous and arterial systems. It is associated with increased morbidity, mortality, psychological and financial burden. The exact incidence of cancer associated thrombosis is not known in India. Appropriate prevention and treatment of cancer-associated thrombosis is vital to reduce its burden on patients with cancer and on the health system at large.

The management of CAT is associated with many clinical challenges. Cancer patients who experience VTE fare worse with respect to major bleeding and death, compared with those who do not have VTE. More recently, the direct-acting oral anticoagulants are being evaluated for the treatment of CAT, and their use in the cancer setting is increasing. Despite a strong evidence base for best practice, adherence to clinical guidelines is variable and decision-making is inconsistent across the specialties involved in the management of CAT resulting in suboptimal care which can have a negative impact on patient safety, quality of life and treatment expenses. A holistic multidisciplinary approach to CAT is essential. At the Tata Memorial hospital a dedicated cancer thrombosis clinic has been established for over last 10 years and we have formed a multidisciplinary hospital cancer thrombosis working group.

• Meeting will focus on recent advances in the understanding of the pathogenesis, prevention and treatment of thrombosis in cancer patients, both from the basic and clinical research points of view. We have several international and national experts to deliberate on these issues. We look forward for your participation in this meeting

Key Points :-

- VTE prophylaxis in cancer patients
- Challenges in anticoagulation in the cancer patient
- Interventional procedures in cancer associated thrombosis
- Newer oral anticoagulants

Organizing Chairperson: Dr. Aruna Alahari Dhir

Organizing Secretary: Dr. Sheela Sawant, Dr. Anupriya Daddi,
Dr. Suyash Kulkarni

For Registration & other details, please contact:

Ms. Meenakshi / Ms. Tejashri

Clinical Research Secretariat (CRS) and DAE-CTC
3rd Floor Main Building, Tata Memorial Hospital,
Parel, Mumbai 400012, India

Tel: +91-22-24177000; Extn 4254 / Fax: +91-22-24168604

E-mail: tmhebm@gmail.com, events@tmc.gov.in

Web: <https://tmc.gov.in>



Tata Memorial Centre XVII Annual Conference on Evidence Based Management of Cancers in India



Clinical Genomics in Hemato-Oncology Hepato-Pancreato-Biliary Malignancies Cancer associated thrombosis

28th February to 3rd March 2019

Venue

Prof. R. D. Choksi Auditorium, Tata Memorial Hospital, Mumbai

Organized by :

Tata Memorial Centre, Mumbai
Clinical Research Secretariat (CRS) and
Department of Atomic Energy Clinical Trials Centre (DAE- CTC)



28th February to 3rd March 2019

**XVII Annual Conference on
Evidence Based Management of Cancers in
India**

**Clinical Genomics in Hemato-Oncology
Hepato-Pancreato-Biliary Malignancies
Cancer associated thrombosis**

Dear All

The Tata Memorial Centre cordially invites you to the 17th conference on "Evidence Based Management of Cancers in India- EBM 2019" to be held from 1st March to 3rd March 2019. This three day meeting will merge with the "Hospital Day Celebration" which will be held on 2nd March 2019. The Tata Memorial Hospital has pioneered the cause of EBM in oncology in India and has been conducting the annual meeting on EBM in common cancers for the past sixteen years.

Each year we have focused on different aspect of cancer care; collated and published the best available evidence in the form of "EBM book" which is also easily accessible at our official website. This meeting helps busy clinicians from all over the country and abroad to get updated on the best available evidence in oncology in a span of 2-3 days, thereby translating into better overall patient care. This year we will be focusing on HPB Malignancies, Cancer associated thrombosis and Clinical Genomics in Hemato-Oncology.

Renowned international and national faculty members will cover the above topics in a very focused and succinct manner. The target audience for the meeting is surgical, radiation, medical oncologist, anesthesiologists, radiologists, pathologists, physicians, basic scientists, general medicine practitioners, researchers and residents training in any of the specialties.

We look forward to welcoming you at this annual event.

Prof R A Badwe,
Director, Tata Memorial Centre



DR. RAJENDRA BADWE
Director
Tata Memorial Centre

Clinical Genomics in Hemato-Oncology

28th February to 1st March 2019

In the last decade, due to advancements in sequencing technologies we have gained a deeper understanding of the cancer genome. We now know that haematological malignancies are highly heterogeneous due to gene mutations, copy number alterations and gene fusions. This knowledge has led to changes in classification, prognostication, monitoring and therapy of blood cancers. The current understanding is that no patient is truly identical, in fact, the typical patient may not really exist. We have come full circle from protocol based therapy to individualizing treatment as per the patient's disease biology. The era of personalized medicine is truly upon us.

This meeting will focus on recent advancements of next generation sequencing technologies and their application to hematological malignancies. The focus will be on the importance of genomics and application to blood cancers. In addition, we will seek perspective from key international & national leaders on their experience so far. In addition, we will also discuss laboratory aspects of genomics such as panel design, standardization of NGS assays and data analytics. This meeting will be preceded by a 3 day hands-on informatics workshop.

" Through this meeting, we will also discuss challenges faced by molecular pathologists from India with regards to implementation of next-generation sequencing in the clinic. We will then brainstorm possible solutions so as to accelerate this clinical implementation"

Key Points :-

- Perspectives from national and international leaders on the clinical relevance of genomics in haemato-oncology
- Laboratory aspects of next generation sequencing: optimal panels, assay set up and quality control
- Computational approaches and newer concepts pertaining to genome sequencing
- Assessment of minimal residual disease in acute leukemia using next generation sequencing
- Data from Indian centers and panel discussion

Organizing Chairpersons: Dr. P G Subramanian & Dr. Sumeet Gujral

Organizing Secretary: Dr. Nikhil Patkar

Hepato-Pancreato-Biliary Malignancies

1st to 3rd March 2019

HPB malignancies remain an important issue in the world of oncology mainly due to poor outcomes and requires high level of surgical and medical expertise. The emergence of multimodality treatment over the last decade has resulted in a paradigm shift in the management of HPB malignancies.

At Tata Memorial Centre, GI malignancies are second only to head & Neck malignancies with more than 9000 patients being registered annually. With more than 40% of these being HPB malignancies, we perform ~ 500 HPB oncological resections and are the single largest center in India treating HPB malignancies.

Evolution and implementation of various neoadjuvant treatment protocols, especially in borderline resectable pancreatic and gall bladder cancers have helped us to stretch the surgical limits and keep us in the forefront of oncological advancement. Specialized multidisciplinary clinics in HPBlike Liver clinic and NET clinic oversee evidence based standardization of treatment for all patients. The MDT approach has resulted in vastly improved outcomes for our patients.

•This EBM conference will be led by a galaxy of national and international authorities in the field of HPB malignancies. The goal is to critically review and present the best available evidence and evolve management practices, which can be easily assimilated into clinical practice across the country.

Key Points :-

- Surgical advances in HPB malignancies
- Neoadjuvant approaches in Borderline resectable pancreatic cancers (BRPC) & Gall bladder cancers.
- What's new in Pancreatic neuroendocrine tumours (pNETs) ?
- Moving beyond BCLC in the treatment of HCC.
- Stereotatic radiotherapy in liver and pancreatic tumors (Hands on Workshop).

Organising Chairperson: Prof. Shailesh V. Shrikhande

Organising Secretary: Prof. Mahesh Goel